Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon
- PMID: 12694851
- DOI: 10.1016/s0360-3016(03)00089-0
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon
Abstract
Purpose: To assess whether conformal radiotherapy (CRT) after incomplete surgery or biopsy for pure oligodendrogliomas and mixed gliomas results in decreased long-term sequelae without impairing local control and while reducing irradiated volume.
Materials and methods: Twenty-six consecutive patients who presented with pure (21) or mixed (5) oligodendrogliomas and who were given incomplete resections were treated according 3 different strategies: CRT alone (12), chemotherapy followed by CRT (4), and chemotherapy and delayed CRT at the time of tumor progression (10). CRT consisted of multiple noncoplanar fields. Median dose was 60 Gy. Quality of CRT was assessed using tumor and normal tissue conformal indexes. The location of recurrences was assessed with MRI and dosimetric data. Late sequelae were assessed by a questionnaire exploring professional outcome, and also by a Mini Mental State Examination test.
Results: The mean overall survival was 5.2 years. Fifteen patients experienced a local relapse. All but 1 occurred in the 95% isodose. Among 11 nonevolutive patients, 6 have a full-time or part-time job.
Conclusions: Despite CRT, infield recurrence was a common feature in patients with oligodendrogliomas and mixed tumors. Further research, including molecular biology typing of tumors and type of treatment, is warranted to improve survival and quality of life.
Similar articles
-
PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.Neurosurgery. 1998 Nov;43(5):1066-73. doi: 10.1097/00006123-199811000-00035. Neurosurgery. 1998. PMID: 9802850 Clinical Trial.
-
The treatment of anaplastic oligodendrogliomas and mixed gliomas.Neurosurgery. 1993 Mar;32(3):365-70; discussion 371. doi: 10.1227/00006123-199303000-00005. Neurosurgery. 1993. PMID: 8455760
-
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.Oncology (Williston Park). 2015 Apr;29(4):264, 266-8. Oncology (Williston Park). 2015. PMID: 25952490 No abstract available.
-
Aggressive oligodendroglioma: a chemosensitive tumor.Recent Results Cancer Res. 1994;135:127-33. doi: 10.1007/978-3-642-85039-4_13. Recent Results Cancer Res. 1994. PMID: 8047688 Review. No abstract available.
-
Radiochemotherapy of malignant glioma in adults. Clinical experiences.Strahlenther Onkol. 2003 Apr;179(4):219-32. doi: 10.1007/s00066-003-1027-y. Strahlenther Onkol. 2003. PMID: 12707711 Review.
Cited by
-
Basic Characteristics of Oligodendrogliomas at the Shohada-e Tajrish Hospital (2008 to 2014).Iran J Pathol. 2017 Summer;12(3):241-247. Epub 2017 Jul 1. Iran J Pathol. 2017. PMID: 29531549 Free PMC article.
-
Incidence of and survival from oligodendroglioma in Denmark, 1943-2002.Neuro Oncol. 2009 Jun;11(3):311-7. doi: 10.1215/15228517-2008-105. Epub 2008 Dec 9. Neuro Oncol. 2009. PMID: 19066344 Free PMC article.
-
Influences on cognitive outcomes in adult patients with gliomas: A systematic review.Front Oncol. 2022 Aug 5;12:943600. doi: 10.3389/fonc.2022.943600. eCollection 2022. Front Oncol. 2022. PMID: 36033458 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials